WallStSmart
SKYE

Skye Bioscience, Inc. Common Stock

NASDAQ: SKYE · HEALTHCARE · BIOTECHNOLOGY

$0.88
-1.71% today

Updated 2026-04-30

Market cap
$22.94M
P/E ratio
P/S ratio
EPS (TTM)
$-1.30
Dividend yield
52W range
$1 – $6
Volume
0.6M

Skye Bioscience, Inc. Common Stock (SKYE) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item20122013201420152016201720182019202020212022202320242025
Revenue$16243.00$339926.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Revenue growth (YoY)+1992.8%-100.0%
Cost of revenue$5356.00$131341.00$9953.00$14916.00$8038.00$1544.00$1462.00$1872.00$34131.00$114998.00$124251.00$298640.00$723352.00
Gross profit$10887.00$208585.00$-9953.00$-14916.00$-8038.00$-1544.00$-1462.00$-1872.00$-34131.00$-114998.00$-124251.00$-298640.00$-723352.00
Gross margin67.0%61.4%
R&D$227500.00$576093.00$939040.00$311302.00$329966.00$2.24M$1.94M$2.93M$6.01M$5.82M$18.70M$42.36M
SG&A$6374.00$120403.00$2.50M$3.74M$3.53M$3.55M$4.36M$4.39M$4.34M$4.92M$6.09M$7.85M$17.73M$15.80M
Operating income$4117.00$-7242.00$-2.73M$-4.32M$-4.47M$-3.86M$-4.69M$-6.63M$-6.29M$-7.85M$-18.31M$-34.74M$-30.19M$-58.16M
Operating margin25.3%-2.1%
EBITDA$4755.00$-7242.00$-3.85M$-4.69M$2.04M$-5.85M$-7.72M$-18.70M$-36.62M$-25.29M$-57.44M
EBITDA margin29.3%-2.1%
EBIT$4117.00$-1631.00$-2.73M$-4.32M$-4.47M$-3.09M$-4.69M$2.04M$-5.85M$-7.75M$-18.81M$-36.74M$-25.59M$-58.16M
Interest expense$638.00$2151.00$522335.00$0.00$667.00$94763.00$1.00M$706385.00$767511.00$663774.00$906270.00$967602.00
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$4509.00$-120403.00$-2.73M$-4.84M$-3.18M$-3.09M$-19.19M$1.05M$-6.56M$-8.52M$-19.48M$-37.64M$-26.57M$-55.92M
Net income growth (YoY)-2770.3%-2170.7%-77.1%+34.4%+2.6%-520.4%+105.5%-723.7%-29.9%-128.6%-93.2%+29.4%-110.5%
Profit margin27.8%-35.4%